Skip to content

Disc Medicine IRON Enterprise value

Enterprise value at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$158.92B-2.6%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$109.92B-9.5%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$6.54B+130%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$1.9B+15.2%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$2.39B+51.2%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$2.68B+65.5%

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Calculated from Disc Medicine’s reported figures.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's enterprise value?
Disc Medicine (IRON) reported enterprise value of $2.38B in Q1 2026.
How has Disc Medicine's enterprise value changed year-over-year?
Disc Medicine's enterprise value increased by 46.7% year-over-year, from $1.62B to $2.38B.
What is the long-term trend for Disc Medicine's enterprise value?
Over 5 years (2020 to 2025), Disc Medicine's enterprise value has grown at a 52.2% compound annual growth rate (CAGR), from $359.48M to $2.94B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.